We are live on ! Find out more
NVS icon

Novartis

1,172 hedge funds and large institutions have $24.4B invested in Novartis in 2019 Q4 according to their latest regulatory filings, with 156 funds opening new positions, 412 increasing their positions, 387 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

184% more first-time investments, than exits

New positions opened: 156 | Existing positions closed: 55

64% more funds holding in top 10

Funds holding in top 10: 1423 (+9)

55% more call options, than puts

Call options by funds: $200M | Put options by funds: $129M

15% more capital invested

Capital invested by funds: $21.2B → $24.4B (+$3.18B)

8% more funds holding

Funds holding: 1,0901,172 (+82)

6% more repeat investments, than reductions

Existing positions increased: 412 | Existing positions reduced: 387

0.54% more ownership

Funds ownership: 9.57%10.11% (+0.54%)

Holders
1,172
Holders Change
+82
Holders Change %
+7.52%
% of All Funds
23.09%
Holding in Top 10
23
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+64.29%
% of All Funds
0.45%
New
156
Increased
412
Reduced
387
Closed
55
Calls
$200M
Puts
$129M
Net Calls
+$71M
Net Calls Change
+$62.6M
Name Holding Trade Value Shares
Change
Change in
Stake
State Street
26
State Street
Massachusetts
$210M -$45.1M -503,078 -18%
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$207M +$493K +5,494 +0.3%
MNG
28
Manning & Napier Group
New York
$205M -$22.8M -253,817 -11%
Neuberger Berman Group
29
Neuberger Berman Group
New York
$197M +$5.58M +62,243 +3%
Invesco
30
Invesco
Georgia
$188M -$5.42M -60,366 -3%
Capital Research Global Investors
31
Capital Research Global Investors
California
$181M +$344K +3,839 +0.2%
EARNEST Partners
32
EARNEST Partners
Georgia
$180M -$3.44M -38,288 -2%
ClearBridge Investments
33
ClearBridge Investments
New York
$165M +$15.4M +171,577 +11%
Boston Partners
34
Boston Partners
Massachusetts
$164M -$15.7M -174,425 -9%
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$142M +$3.11M +34,634 +2%
Principal Financial Group
36
Principal Financial Group
Iowa
$137M +$6.74M +75,130 +5%
Goldman Sachs
37
Goldman Sachs
New York
$134M +$5.61M +62,520 +5%
SEI Investments
38
SEI Investments
Pennsylvania
$121M +$5.69M +63,402 +5%
Rockefeller Capital Management
39
Rockefeller Capital Management
New York
$117M -$1.68M -18,723 -1%
Ameriprise
40
Ameriprise
Minnesota
$115M +$16.5M +183,560 +18%
RJA
41
Raymond James & Associates
Florida
$114M +$2.17M +24,154 +2%
AG
42
Aperio Group
California
$112M -$4.74M -52,814 -4%
SI
43
Scharf Investments
California
$108M -$3.24M -36,118 -3%
Natixis Advisors
44
Natixis Advisors
Massachusetts
$105M +$7.38M +82,276 +8%
Westfield Capital Management
45
Westfield Capital Management
Massachusetts
$104M +$98.3M +1,095,518 New
VOYA Investment Management
46
VOYA Investment Management
Georgia
$85.9M -$943K -10,513 -1%
Charles Schwab
47
Charles Schwab
California
$85.7M +$12.8M +142,947 +19%
MAM
48
Madison Asset Management
Wisconsin
$83.1M +$78.8M +877,651 New
Macquarie Group
49
Macquarie Group
Australia
$82.2M -$731K -8,143 -0.9%
Chevy Chase Trust
50
Chevy Chase Trust
Maryland
$81M +$3.12M +34,790 +4%

NVS Hedge Fund Activity: Q4 2019 in Review

1,172 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2019, worth a combined $24.4B — up 15% from $21.2B a quarter earlier.

Buyers outnumbered sellers: 156 funds opened new NVS positions and 55 closed out — a net gain of 101 holders — while 412 added to existing stakes and 387 trimmed.

The largest buyer was Loomis, Sayles & Company, adding an estimated $284M. The largest seller was Dodge & Cox, cutting an estimated $140M.

  • 1,172 institutional investors held Novartis (NVS) as of Q4 2019, up from 1,090 in Q3 2019.
  • Funds reported $24.4B of Novartis stock for Q4 2019, up 15% quarter-over-quarter.
  • 156 funds opened new Novartis positions in Q4 2019 and 55 closed out, a net change of +101 holders.
  • The largest Novartis buyer in Q4 2019 was Loomis, Sayles & Company, an estimated $284M added.
  • The largest Novartis seller in Q4 2019 was Dodge & Cox, an estimated $140M sold.

Based on aggregated 13F filings for Q4 2019.